Comparative Pharmacology
Head-to-head clinical analysis: LYBALVI versus NUPLAZID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYBALVI versus NUPLAZID.
LYBALVI vs NUPLAZID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYBALVI is a combination of olanzapine and samidorphan. Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C, dopamine D1-D4, histamine H1, and alpha1-adrenergic receptors. Samidorphan is an opioid receptor antagonist with high affinity for mu-opioid receptors, hypothesized to reduce olanzapine-associated weight gain by blocking opioid receptors in the central nervous system.
Selective serotonin 5-HT2A receptor inverse agonist and antagonist; also has moderate affinity for 5-HT2C and 5-HT1A receptors.
Olanzapine 10 mg / samidorphan 10 mg orally once daily.
34 mg orally once daily.
None Documented
None Documented
Terminal half-life ~20-30 hours; supports once-daily dosing.
Terminal elimination half-life is approximately 50 hours (range 40-70 hours), allowing once-daily dosing.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40%; Biliary: minor.
Fecal (approximately 60%) as unchanged drug and metabolites; renal (approximately 13%) as unchanged drug and metabolites.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic